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Abstract
Transactive response DNA-binding protein 43 (TDP-43) is a major pathological protein in frontotemporal dementia (FTD)
and amyotrophic lateral sclerosis (ALS). There are many disease-associated mutations in TDP-43, and several cellular and
animal models with ectopic overexpression of mutant TDP-43 have been established. Here we sought to study altered
molecular events in FTD and ALS by using induced pluripotent stem cell (iPSC) derived patient neurons. We generated
multiple iPSC lines from an FTD/ALS patient with the TARDBP A90V mutation and from an unaffected family member who
lacked the mutation. After extensive characterization, two to three iPSC lines from each subject were selected, differentiated
into postmitotic neurons, and screened for relevant cell-autonomous phenotypes. Patient-derived neurons were more
sensitive than control neurons to 100 nM straurosporine but not to other inducers of cellular stress. Three disease-relevant
cellular phenotypes were revealed under staurosporine-induced stress. First, TDP-43 was localized in the cytoplasm of a
higher percentage of patient neurons than control neurons. Second, the total TDP-43 level was lower in patient neurons
with the A90V mutation. Third, the levels of microRNA-9 (miR-9) and its precursor pri-miR-9-2 decreased in patient neurons
but not in control neurons. The latter is likely because of reduced TDP-43, as shRNA-mediated TDP-43 knockdown in rodent
primary neurons also decreased the pri-miR-9-2 level. The reduction in miR-9 expression was confirmed in human neurons
derived from iPSC lines containing the more pathogenic TARDBP M337V mutation, suggesting miR-9 downregulation might
be a common pathogenic event in FTD/ALS. These results show that iPSC models of FTD/ALS are useful for revealing stress-
dependent cellular defects of human patient neurons containing rare TDP-43 mutations in their native genetic contexts.
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Introduction
Frontotemporal dementia (FTD), the second most common
form of presenile dementia, and amyotrophic lateral sclerosis
(ALS), a neurodegenerative disease that primarily affects motor
neurons in the spinal cord and brain, are regarded as closely
related conditions [1]. Genetic mutations and pathological
proteins associated with both diseases include valosin-containing
protein [2,3], multivesicular body protein 2B [4,5], ubiquilin 2 [6],
chromosome 9 open reading frame 72 [7,8], transactive response
DNA-binding protein 43 (TDP-43) and fused in sarcoma (FUS)
[9–13].
TDP-43 is a disease-related protein that links FTD and ALS.
TDP-43 has two RNA recognition motifs and a glycine-rich region
and is implicated in multiple aspects of RNA metabolism [14,15].
Among these, TDP-43 has been linked to the processing of
microRNAs (miRNAs) [16–18]. MiRNAs are small noncoding
RNAs that regulate gene expression post-transcriptionally by
degrading their target mRNAs or repressing their translation
[19,20]. Although potential involvement of miRNAs in neurode-
generation has been increasingly appreciated, information about
their regulation and function in diseased human neurons remains
scarce [21].
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Modeling neurodegenerative diseases with TDP-43 pathology
in animal models has been challenging. Although loss of nuclear
TDP-43 and intracellular TDP-43 aggregates are common
pathological features in neurons of FTD and ALS patients,
disease-causing mutations in the gene are rare. Thus, in most
patients, other contributing genetic factors appear to function
upstream of TDP-43 during disease initiation and progression,
which is difficult to model in animals. Moreover, the proper
expression level of TDP-43 is critically important for its function.
Ectopic expression of wildtype TDP-43 alone can be toxic, and
TDP-43 itself is under complex autoregulation [22–25]. Deletion
of TDP-43 in mice is lethal [26–28], highlighting its importance,
but its conditional knockout shows disease–relevant phenotypes
[29–31].
The ability to generate human induced pluripotent stem cells
(iPSCs) from somatic cells [32] allows disease phenotypes of
human neurons to be analyzed in the context of the unique genetic
background of individual patients. Indeed, iPSCs have been
generated from patients with ALS and other neurodegenerative
diseases [33–40]. In this study, we generated iPSC lines from an
FTD/ALS patient with TARDBP A90V mutation and from a
healthy family member with no known mutations. We character-
ized neurons from this mutation and identified cell-specific
phenotypes. Among these, we identified reduced miR-9 expression
as a molecular defect that is downstream of TDP-43 and common
to human neurons with TARDBP A90V or M337V mutations.
Results
Generation of patient-specific iPSC lines
Multiple iPSC lines derived from two patients were examined in
this study. Two lines were previously generated from a 56-year old
male with the TARDBP M337V mutation [35]. In this study, we
also generated iPSC lines from a subject with FTD/ALS who was
a patient at the Memory and Aging Center, University of
California, San Francisco. The patient had an A90V mutation
in TARDBP, and his skin biopsy was obtained at the age 75 years.
To minimize the difference in genetic background, a skin biopsy
was also obtained from a 65-year-old family member who had no
TDP-43 mutations or clinical symptoms of FTD and lacked the
A90V mutation. The patient and control were tested negative for
the common FTD genes including GRN, MAPT and C9ORF72.
The patient’s clinical symptoms and family history are described in
detail in File S1.
Fibroblasts were derived from skin biopsies of both subjects.
Genomic DNA was isolated from cultured fibroblasts, and the
region flanking the expected TARDBP A90V mutation was PCR-
amplified and sequenced to confirm the presence of the
c.269C.T (A90V) mutation (Fig. 1A). The fibroblasts were
reprogrammed with retrovirus expressing OCT4, SOX2, KLF4,
and cMYC as described (Fig. 1B) [41]. After 4 to 5 weeks, iPSC
colonies were manually picked and transferred to a Matrigel-
coated plate. At least 20 clones from each individual were obtained
for further characterization.
To identify fully reprogrammed iPSC lines, we performed
several assays. First, to confirm that ectopically expressed
reprogramming factors were effectively silenced; we used quanti-
tative RT-PCR (qRT-PCR) to measure the endogenous and total
levels (expressed from both the endogenous locus and the
retroviral vector) of each reprogramming factor. The total level
was comparable with that expressed from the endogenous locus,
consistent with silencing of the transgene (Fig. 1C). Next, we
selected 2 iPSC lines from the family member and 3 lines from the
patient. All these lines maintained a normal karyotype (Fig. 1D
and Fig. S1) and all continuously expressed pluripotent stem cell
markers including NANOG, SSEA4, OCT4, TRA-1-60, and
TRA-1-81 (Fig. 2A). We then examined the differentiation
capability of the iPSCs in vitro through the formation of EBs.
Spontaneous differentiation into derivatives of the three embry-
onic germ layers was confirmed after 1 week of cell culture
(Fig. 2B). Altogether, these results indicate that the reprogramming
was successful. The five selected iPSC lines were used for further
studies below.
Differentiation of iPSCs with TDP-43 mutations into
functional neurons
The most prominent clinical phenotypes of the patient during
20 years of slow disease progression after the first diagnosis were all
typical symptoms of FTD. To establish a human neuronal model
of TDP-43-related FTD, we differentiated iPSCs with the
TARDBP A90V and M337V mutations into postmitotic human
neurons using a protocol for differentiating human embryonic
stem cells into neural progenitor cells expressing the telencephalon
marker BF1 [42,43]. Briefly, EBs were formed and cultured in
suspension before the induction of rosette formation with basic
fibroblast growth factor 2 in serum-free medium containing N2
supplement for 12 days. Rosette cells were isolated and expanded
in suspension culture for 21 days to form neurospheres. To
differentiate dissociated neural progenitor cells into mostly
postmitotic neurons, brain-derived neurotropic factor and glial
cell line–derived neurotropic factor were included in the culture
medium for 14 days (Fig. 3A).
After neuronal differentiation, about 65% of cells differentiated
from control or patient iPSC lines with the TARDBP A90V
mutation were immunopositive for the neuronal marker TUJ1
(Fig. 3B, C). A similar percentage of TUJ1-positive cells was
obtained from neuronal differentiation of M337V and its control
iPSC lines (data not shown). Moreover, the percentages of
excitatory and inhibitory neurons were indistinguishable (Fig.
S2), indicating the reproducibility of each differentiation process
and the A90V mutation did not affect neuronal differentiation.
The morphology and number of neurites were similar in neurons
from the FTD/ALS patient and the family member (Fig. 3D). At 4
to 5 weeks after induction, all recorded neurons differentiated from
control and patient iPSCs generated normal action potentials
(Fig. 3E). We also determined whether control and patient iPSC
neurons could form functional synapses. After terminal differen-
tiation for 4 to 5 weeks, 80% of recorded control neurons, but only
about 50% of patient neurons, showed spontaneous synaptic
currents (Fig. 3F). Although the amplitude of spontaneous synaptic
currents was similar (control neurons: 27.1061.95 pA; patient
neurons: 31.5862.48 pA), the frequency of postsynaptic currents
was lower in the patient neurons (0.0960.01 versus 0.2660.05
events/second) (Fig. 3F). These results suggest there might be a
significant functional difference between control and patient
neurons, which should be further investigated in the future.
Patient Neurons with the TARDBP A90V Mutation Show
Stress-Dependent Cellular and Molecular Phenotypes
One of the challenges in using iPSCs to model age-dependent
neurodegenerative disease is whether one can observe any disease-
relevant phenotypes in cell culture. We hypothesized that under
certain cellular stress, patient neurons would exhibit cellular and
molecular phenotypes distinct from those of control neurons. First
we examined the viability of neurons treated with different
inducers of cellular stress. Patient and controls neurons were
equally sensitive to sorbitol, an inducer of osmotic and oxidative
iPSC Model of FTD/ALS with a TDP-43 Mutation
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stress (Fig. S3A) [44], sodium arsenite (Fig. S3B) and tBOOH (Fig
S3C), both inducers of oxidative stress [45,46]. However, more
patient neurons died after treatment with 100 nM staurosporine
(STS) (Fig. 4A), an inducer of apoptotic cell death [47].
Redistribution of TDP-43 from the nucleus to the cytoplasm is a
characteristic of neurons in brain and spinal cord sections from
FTD and ALS patients [9]. Immunostaining to detect the
subcellular distribution of TDP-43 in patient neurons revealed
that, under normal conditions, TDP-43 was present in the nucleus
in the majority of cells (Fig. 4B). However, in response to100 nM
STS, TDP-43 was mislocalized from nucleus to cytoplasm in more
patient neurons than control neurons (Fig. 4C, 4D). FUS, another
RNA binding protein associated with FTD and ALS [46],
remained in the nucleus in both control and patient neurons after
STS treatment (Fig. 4E, 4F).
Increasing evidence suggests that either increased or decreased
TDP-43 expression is associated with neurodegeneration
[14,15,24,30]. To examine TDP-43 expression in patient neurons
under cellular stress, we measured TDP-43 in the insoluble and
soluble fractions of patient neurons with the TARDBP A90V
mutation treated with STS. The cells were extracted first with
RIPA buffer and then with urea buffer to recover insoluble TDP-
43, and analyzed by western blot. The TDP-43 level in the
insoluble fraction was similar in untreated control and patient
neurons with the TARDBP A90V mutation, but levels were
significantly lower in patient neurons after STS treatment (Fig. 5A,
B). Similarly, in the soluble fraction, the TDP-43 level was
comparable in untreated patient and control neurons (Fig. 5C).
However, after STS treatment, TDP-43 (Fig. 5D) but not FUS
(Fig. S4A) was significantly lower in patient neurons with the
TARDBP A90V mutation, consistent with the notion that loss of
TDP-43 activity is also associated with neurodegenerative
processes. This decrease is likely in part due to transcriptional
regulation since TDP-43 mRNA level is reduced in patient
neurons after STS treatment (Fig. S4B). This decrease may not be
contributed by the difference in protein stability between TDP-43
WT and TDP-43 A90V since STS treatment does not seem to
affect the steady state level of transfected TDP-43 A90V compared
Figure 1. Generation and characterization of FTD/ALS patient-specific iPSC lines with the TDP-43 A90V mutation. (A) Sequencing of
genomic DNA from patient fibroblasts confirmed the presence of the missense TDP43 A90V (c.269 C.T) mutation. (B) Schematic representation of
the steps from the collection of patient fibroblasts to the derivation of postmitotic neurons. Fibroblasts, iPSCs and neurons were immunostained with
TDP-43, NANOG and TUJ1 antibodies, respectively. (C) Quantitative RT-PCR analysis of the levels of total and endogenous expression of OCT4, CMYC,
SOX2, and KLF4 in iPSC and H9 ESC lines. Values were normalized to GAPDH levels. (D) No chromosomal abnormalities were found in any of the
selected iPSC lines. The karyotypes of control line 37L20 and patient line 36L10 are shown.
doi:10.1371/journal.pone.0076055.g001
iPSC Model of FTD/ALS with a TDP-43 Mutation
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with TDP-43 WT (Fig. 5E, F). Indeed, there is no intrinsic
difference in the protein stability of transfected TDP-43 WT and
TDP-43 A90V (Fig. S5A, B). Moreover, both transfected TDP-43
WT and TDP-43 A90V could effectively suppress the expression
of endogenous TDP-43, indicating a normal autoregulatory
function (Fig. S5C, D).
TDP-43 has been implicated in the miRNA pathway [16], and
alterations in the activity of several miRNAs have been associated
with neurodegeneration [21]. Among them, miR-9, a brain-
specific miRNA whose nucleotide sequence is highly conserved
through evolution, is implicated in several neurodegenerative
diseases and of great interest [49]. Indeed, the level of miR-9
(Fig. 6A) was significantly lower in patient neurons with the
TARDBP A90V mutation than control neurons only after STS
treatment. This decrease did not seem to be due to a defect in the
miRNA-processing pathway, since STS also reduced the levels of
both pre-miR-9-2 and pri-miR-9-2 in patient neurons (Fig. 6B, C).
Moreover, pri-miR-124-1, the most abundant brain-specific
miRNA, was not affected (Fig. S6A). Pri-miR-9-2 and pri-miR-
124-1 were analyzed here because they are the most abundant
among three miR-9 or miR-124 alleles, separately [50,51]. In
neurons with the TARDBP M337V mutation, the levels of pre-
miR-9-2 and pri-miR-9-2 were also significantly lower after STS
treatment than that in neurons derived from two control
individuals (Fig. 6D). Interestingly, even without STS treatment,
miR-9-2 expression was already lower in neurons with the
TARDBP M337V mutation (Fig. 6D), consistent with the more
pathogenic nature of the M337V mutation. To demonstrate that
the decrease in miR-9a expression resulted directly from reduced
TDP-43 function under cellular stress, we used mouse TDP-43-
specific shRNAs (Fig 6E). TDP-43 knockdown in mouse primary
cortical neurons indeed reduced the expression of pri-miR-9-2
(Fig. 6F) but not miR-124-1 (Fig. S6C).
Discussion
To better understand the molecular pathogenic events in FTD,
we used human neurons of telencephalon lineage differentiated
from iPSCs with the TARDBP M337V mutation [35] or with the
TARDBP A90V mutation as generated and characterized here.
Using this system, we found that patient neurons with the
TARDBP A90V mutation are less viable under cellular stress with
the kinase inhibitor staurosporine treatment than control neurons.
In these patient neurons, the percentage of cells with mislocalized
cytoplasmic TDP-43 was increased. The expression of TDP-43
was also significantly decreased under cellular stress induced by
STS. Moreover, miR-9 expression is significantly reduced in
patient neurons with the TARDBP M337V mutation or in neurons
with A90V mutation after STS treatment, revealing another stress-
related molecular defect in patient neurons.
A major advantage of using iPSC-derived human neurons to
study neurodegeneration is the presence of other patient-specific
genetic factors in these cells. Several hundred genetic mutations
may exist in each patient’s genome and their collective contribu-
tion to disease process can be assessed. The A90V mutation is rare
and considered to be a risk factor for FTD/ALS [52,53]. Thus,
examining the A90V mutation alone in animal models without
other genetic modifiers may not be sufficient to reveal disease
mechanisms. The cellular and molecular phenotypes observed
here in iPSC-derived patient neurons are likely due to the overall
genetic and epigenetic makeup of the patient including contribu-
tions from the A90V mutation. Although we used a family
member as negative control to minimize the difference in genetic
background, we understand the results obtained here from one
patient need to be interpreted cautiously and we are aware of the
challenges of generating more iPSC lines from other patients with
the same rare mutation. So it remains to be seen whether neurons
derived from other patients with the same or different TDP-43
mutations exhibit these cellular phenotypes under stress.
It is interesting to note that the A90V patient’s disease
progression after the initial diagnosis was unusually slow and
lasted over two decades, while the partial loss of TDP-43
expression in the patient’s iPSC-derived neurons occurred only
after the treatment with a high concentration of STS. This
decrease in TDP-43 level could be due to the effects of A90V
mutation on nuclear import or in combination with other genetic
factors. These findings support the hypothesis that the A90V
mutation is pathogenic but with a slower kinetics. This observation
stands in contrast to human neurons differentiated from patients
with the M337V mutation where increased TDP-43 aggregates
were observed even without stress treatment [35,36], consistent
with the notion that this mutation is more pathogenic.
Our results also indicate that miR-9 is specifically dysregulated
in stressed patient neurons with the TARDBP A90V mutation,
likely as a direct result of the reduced TDP-43 level observed in
these neurons, as shRNA-mediated knockdown of TDP-43 in
mouse primary cortical neurons also reduced miR-9 expression
(Fig. 6). In human neurons containing the more pathogenic
M337V mutation, miR-9 expression is also reduced even without
STS treatment (Fig. 6). However, it is worth noting that human
neurons in the normal culture conditions are already under
cellular stress. Although total level of TDP-43 may increase in
human neurons containing the TARDBP M337V mutation once
the inter-patient variability is taken into account [36], a number of
studies indicate that the M337V mutation results in the partial loss
Figure 2. Verification of the pluripotency of the iPSC lines with
the TDP-43 A90V mutation. (A) Fluorescence microscopy images of
the expression of the pluripotency markers NANOG, OCT4, SSEA4, TRA-
1-60, and TRA-1-81 in control (37L25) and patient (36L10) iPSC lines.
Scale bar: 20 mm. (B) All iPSC lines differentiated into cells of the three
germ layers, as shown by expression of desmin (mesoderm), TUJ1
(ectoderm), and alpha-fetoprotein (AFP, endoderm). These analyses
indicate iPSC lines generated here are indeed pluripotent. Scale bar:
20 mm.
doi:10.1371/journal.pone.0076055.g002
iPSC Model of FTD/ALS with a TDP-43 Mutation
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of normal TDP-43 function [18,54,55] and increased TDP-43
aggregates in human neurons [35,36]. Thus, normal function of
TDP-43 is compromised in human neurons containing the
M337V mutation. Taken together, these findings support the
notion that partial loss of TDP-43 normal function is also
associated with neurodegeneration in FTD/ALS.
A role for TDP-43 in miRNA regulation has been demonstrated
in previous studies [16–18,56]. Similarly, partial loss of FUS
function also results in a reduced miRNA biogenesis [57]. A
prominent feature of TDP-43 pathology is the depletion of nuclear
TDP-43 in many affected neurons, suggesting a possible significant
pathogenic role for the loss of its normal nuclear function [9].
Moreover, mutations in another miRNA regulating protein FUS
cause ALS [12,13] and wild-type FUS forms inclusions in 5% of
FTD cases [48]. Thus, misregulation of miRNAs and miR-9 in
particular may be a common downstream molecular event of both
disorders. TDP-43 regulates hundreds of targets [25,58,59]. To
what extent miR-9 and specific miR-9 targets contribute to TDP-
43 mediated neurodegeneration remains to be determined. The
availability of different FTD/ALS patients-specific iPSC lines
generated here and from other labs will undoubtedly further
facilitate studies on the miRNA pathway and other pathogenic
mechanisms.
Materials And Methods
Cell Culture and Generation of Human iPSCs
Skin biopsies were collected from a 75-year-old man who had a
TARDBP missense mutation (A90V) and from an unaffected 65-
year-old family member who lacked the mutation. The study was
approved by the Institutional Review Board and Ethics Commit-
tees at the University of California, San Francisco (UCSF), and
written informed consent was obtained in all cases. To protect
patient family privacy, no additional information is presented here.
Primary dermal fibroblasts derived from the explants were
cultured in DMEM supplemented with 10% FBS, nonessential
amino acids, and penicillin/streptomycin and reprogrammed into
iPSCs using four transcription factors (OCT3/4, SOX2, KLF4, and
c-MYC) as described (41). Five weeks after viral transduction,
colonies were transferred to 12-well plates coated with Matrigel
(BD Biosciences) and cultured in mTeSR1 medium (StemCell
Technologies). For expansion, colonies were dissociated with
Accutase and plated on 6-well plates. We also used iPSC lines from
Figure 3. Characterization of iPSC-derived neurons with the TDP-43 A90V mutation. (A) Representative images of each of the five stages
of the neural differentiation. The numbers of days cells are in each stage are listed on the top of each image. (B) Representative image of TUJ1
staining in patient neurons (36L10). (C) Percentage of TUJ1+ cells in control and patient neuronal cultures differentiated from iPSC lines 37L20, 37L25,
36L3 and 36L11. (D) Number of neurites in control and patient neurons differentiated from iPSC lines 37L20, 37L25, 36L3 and 36L10. (E) Sample
recording of normal induced action potentials in response to somatic current injections in control and patient neurons differentiated from iPSC lines
37L20, 37L25, 36L10 and 36L11. (F) Spontaneous synaptic activity of control and patient neurons differentiated from iPSC lines 37L20, 37L25, 36L10
and 36L11.
doi:10.1371/journal.pone.0076055.g003
iPSC Model of FTD/ALS with a TDP-43 Mutation
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a 56-year-old man with the TARDBP M337V mutation and from
two healthy controls [35].
Karyotyping
Karyotyping analysis was carried out by the Cytogenetic
Laboratory at the University of Massachusetts Memorial Medical
Center (Worcester, MA). Cells were analyzed by standard G-
banding technique, and results were interpreted by specialists in
the Cytogenetic Laboratory.
Neuronal Differentiation
iPSCs with either TARDBP A90V mutation generated in this
study or the M337V mutation [35] were differentiated as
described [37,42] with some modifications. Embryoid bodies
(EBs) were cultured in suspension for 6 days and attached to dishes
coated with poly-L-ornithine/laminin. 12–14 days later, rosettes
were collected and grown in suspension as neurospheres. After 3
weeks in culture, the neurospheres were dissociated with Accutase,
and the neurons were plated on glass coverslips coated with poly-
L-lysine/laminin. In most experiments, neurons 2-weeks after the
neurosphere stage were used. For spontaneous differentiation in
vitro, EBs were transferred to Matrigel-coated plates after 6-8 days
as a floating culture for 8 days. Migrating cells from EBs were
stained for markers of the three germ layers and analyzed by
immunofluorescence microscopy. For the analysis on M337V
neurons, two independent differentiation experiments were
Figure 4. Patient neurons with the TDP-43 mutation are more susceptible to staurosporine and display increased TDP-43
mislocalization under stress. (A) Viability of control and patient neurons after exposure to10–100 nM staurosporine (STS) for 24 hours. More
patient neurons die after treatment with 100 nM STS. Values are mean 6 SEM. *: p,0.05 (Student’s t-test). (B) The percentages of TUJ1+ control and
patient neurons with mislocalized TDP43 without any stressor treatment. In Panels A and B, iPSC lines 37L20, 37L25, 36L10 and 36L11 were used. (C,
D) Representative images of TDP-43 and TUJ1 staining in control and patient neurons differentiated from iPSC lines 37L20 and 36L10 after treatment
with 100 nM staurosporine for 24 hours (C) and the percentage of TUJ1+ control and patient neurons showing mislocalized TDP-43 (D). After STS
treatment, more patient neurons show TDP-43 cytoplasmic mislocalization. Some cells are non-neuronal cells, for instance, some cells with large
nuclei are not labeled by MAP2. Values are mean6 SEM. *: p,0.05 (Student’s t-test). (E, F) Representative images of FUS and TUJ1 staining in control
and patient neurons differentiated from 37L20 and 36L11 after treatment with 100 nM staurosporine for 24 hours (E) and the percentage of TUJ1+
control and patient neurons differentiated from 37L20, 37L25, 36L10 and 36L11 showing mislocalized FUS (F). FUS localization is not affected by the
TARDBP A90V mutation.
doi:10.1371/journal.pone.0076055.g004
iPSC Model of FTD/ALS with a TDP-43 Mutation
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performed in which two M337V iPSC lines and one or three
control iPSC lines derived from two control individuals were used.
Immunocytochemistry
Cells were fixed in 4% paraformaldehyde for 10 minutes,
permeabilized with 0.3% Triton X-100 for 10 minutes, and
blocked with 10% BSA for 1 hour at room temperature. Cultures
were then stained overnight at 4uC with goat anti-NANOG
(1:100, R&D, AF1997), mouse anti-OCT3/4 (1:100, Santa Cruz
Biotechnology, sc-5279), mouse anti-SSEA4 (1:100, Abcam,
ab16287), mouse anti-TRA-1-60 (1:50, Chemicon, MAB4360),
mouse anti-TRA-1-81 (1:100, Chemicon, MAB4381), rabbit anti-
desmin (Thermo Scientific; 1:100, RB-9014-P0), mouse anti-a-
fetoprotein (AFP, R&D Systems; 1:200, MAB1368), rabbit
anti-TDP-43 (1:200, Proteintech Group, 10782-2-AP), mouse
anti-TUJ1 (1:500, Promega, G712A), rabbit anti-VGLUT1
(1:500, Synaptic Systems,135303)and rabbit anti-GABA (1:1000,
Sigma, A2052). After incubation with the primary antibodies, the
cells were incubated with fluorescence-conjugated secondary
antibodies and imaged with a Nikon D-Eclipse C1 confocal
microscope or an Olympus IX70 fluorescence microscope.
MTT Assay
After 14 days in culture, human neurons were treated for
24 hours with the following stressors: staurosporine, t-butyl
hydroperoxide, sodium arsenite, and DMSO. The sorbitol
treatment was for 30 minutes. MTT assays were performed with
CellTiter 96 Non-Radioactive Cell Proliferation Assay kit
Figure 5. Cellular stress decreases TDP-43 levels in patient neurons with the TDP-43 A90V mutation. (A) The level of full length TDP-43
in the insoluble fraction of patient neurons remains the same as control neurons without STS treatment but decreases with STS treatment. (B)
Quantification of the experiment in Panel A. (C) TDP-43 level in the soluble fraction of patient neurons decreases after STS treatment. (D)
Quantification of the experiment in Panel C. The relative level of TDP-43 in each lane is normalized with the tubulin band and quantification is based
on three independent experiments. (E) Western blot analysis of the levels of endogenous (Endo) and transfected TDP-43 in cell lines stably expressing
tetracycline (tet)-inducible either wildtype (WT) TDP-43-Flag or TDP-43 A90V-Flag with or without STS treatment. The expression of transfected TDP-
43 WT or TDP-43 A90V is induced by tetracycline. The A90V mutation alone is insufficient to decrease TDP-43 level in this assay. (F) Quantification of
the experiment in Panel E. There is no statistical difference between samples treated with and without STS.
doi:10.1371/journal.pone.0076055.g005
iPSC Model of FTD/ALS with a TDP-43 Mutation
PLOS ONE | www.plosone.org 7 October 2013 | Volume 8 | Issue 10 | e76055
(Promega) according to the manufacturer’s protocol. All experi-
ments were conducted in triplicate.
Western Blots
iPSC-derived neurons were collected and homogenized in lysis
buffer (50 mM Tris-HCl, pH 7.5, 150 mM sodium chloride, 1%
Nondidet P40, and 0.5% sodium deoxycholate, and protein
inhibitor cocktail). Homogenates were centrifuged at 13,000 rpm
at 4uC for 20 minutes, and protein concentration was determined
with the Bradford Assay (Bio-Rad). Proteins (5 mg) were separated
on a 10% polyacrylamide-SDS gel and transferred to a PVDF
membrane. After blocking, the membrane was incubated with
anti-hTDP-43 (1:2,000, Proteintech Group, 10782-2-AP, or
1:1,000, Bethyl A303-223A for Figure 5E and Figure S5) and
anti-tubulin antibodies (1:8,000; Sigma, T6199), and finally with
anti-rabbit or anti-mouse secondary antibodies conjugated with
horseradish peroxidase.
Quantitative RT-PCR
Total RNA was extracted and purified with the miRNeasy kit
(Qiagen) and the Turbo DNA-free kit (Ambion). RNA (300 ng)
was used for reverse transcription reaction with TaqMan reverse
transcription reagent kits (Applied Biosystems). mRNA and
miRNA expression levels were quantified with SYBR Green
Master Mix, TaqMan microRNA assays, or Taqman Universal
PCR master mix (Applied Biosystems). Ct values for each sample
and gene were normalized to GAPDH (mRNA) or U6 (miRNA).
Primer sequences are shown in Table S1.
Lentiviral Production and Mouse Primary Neuronal
Cultures
HEK293T cells were transfected with a mix of 2.6 mg plasmids
expressing TDP-43-specific shRNA (Sigma), 26 ml lentiviral
packaging mix (Sigma), and 16 ml FuGENE 6 (Promega).
Thirty-six to forty-eight hours after transfection, medium contain-
ing viruses was filtered and centrifuged at 23,000 rpm for 2 hours
Figure 6. Expression of miR-9 and its precursors is reduced in patient neurons under stress. (A) Relative expression levels of mature miR-
9 in neurons derived from two control and three patient iPSC lines containing the A90V mutation with or without STS treatment (left panel). The
averages in control and patient neurons are shown on the right. (B) Expression of pre-miR-9. (C) Expression of pri-miR-9-2. The average of different
lines from the same individual is set as 1. The results in A–C were confirmed from additional two independent neuronal differentiation experiments.
(D) The relative expression levels of pri-miR-9-2 and pre-miR-9-2 in neurons derived from two patient iPSC lines containing the TARDBP M337V
mutation was reduced. This result is based on two independent differentiation experiments. (E) TDP-43 levels were greatly decreased in primary
mouse neurons transfected with two TARDBP shRNAs. (F) Expression of pri-miR-9-2 is decreased in primary mouse neurons transfected with TARDBP
shRNA. Values are mean 6 SEM. **: p,0.01 (Student’s t-test).
doi:10.1371/journal.pone.0076055.g006
iPSC Model of FTD/ALS with a TDP-43 Mutation
PLOS ONE | www.plosone.org 8 October 2013 | Volume 8 | Issue 10 | e76055
at 4uC.The supernatant was removed, and the pellet containing
the lentiviral particles was dissolved in 100 ml HBSS overnight and
stored at 280uC. Primary neuronal cultures were obtained from
C57/B6 mice (E18). Cells were plated at a density of 70,000 cells/
well in 12-well plates and transduced with lentiviral particles after
3 days in vitro.
Electrophysiology
Whole-cell perforated patch recordings were performed on
FTD/ALS (n=16) and control (n=15) 4- to 5-week-old neurons
grown in neuron medium containing 0.5% FBS on acid-etched
coverslips. The recording micropipettes (tip resistance 3 to 6 MV)
were tip-filled with internal solution composed of 115 mM K-
gluconate, 4 mM NaCl, 1.5 mM MgCl2, 20 mM HEPES, and
0.5 mM EGTA (pH 7.4) and back-filled with the same internal
solution containing 200 mg/ml amphotericin B (Calbiochem).
Recordings were made with an Axopatch 200B amplifier (Axon
Instruments). Signals were sampled at 10 kHz and filtered at
2 kHz. Whole-cell capacitance was fully compensated; series
resistance was uncompensated but monitored during the exper-
iment by the amplitude of the capacitive current in response to a
5-mV pulse. The bath was constantly perfused with fresh HEPES-
buffered saline composed of 115 mM NaCl, 2 mM KCl, 10 mM
HEPES, 3 mM CaCl2, 10 mM glucose, and 1.5 mM MgCl2
(pH 7.4). For voltage-clamp recordings, cells were clamped at260
to 280 mV; Na+ currents and K+ currents were stimulated by
voltage step depolarization. Command voltage varied from250 to
20 mV in 10-mV increments. For current-clamp recordings,
induced action potentials were stimulated with current steps from
20.2 to 0.5 nA. All recordings were performed at room
temperature.
Stable Cell Lines with Inducible TDP-43 Expression
Wildtype TDP-43 cDNA (HindIII-BamHI) was generated by
PCR amplification and 2XFLAG tag was added at its C-terminal
using primers (59-GCGAAGCTTATGTCTGAATATATTC-
GGGTAAC-39 and 59-GCGGATCCTTACTTGTCATCGT-
CGTCCTTGTAGTCCTTGTCATCGTCGTCCTTGTAGTC
CATTCCCCAGCCAGAAGACTTAG-39). The TDP-43 PCR
fragment was inserted into the polylinker of pcDNA5-TetO
(Invitrogen) to make TDP-FLAG plasmid. A90V mutation was
made by primer based Quick Change Method (Stratagene). 2 mg
TDP-FLAG or A90V-FLAG constructs were transfected into
HEK293 cells together with 0.2 mg of pOG44 using 7 ml of
TransIT-293 (Mirus). Cell lines stably expressing TDP-FLAG or
A90V-FLAG were generated by treating the cells with several
rounds of Blasticidin (15 mg/ml) and Hygromycin (100 mg/ml)
selection. To induce transgene expression, tetracycline (Tet;
500 ng/ml) (Sigma) was added at different time points in the
absence or presence of STS.
To examine TDP-43 stability, 500 ng/ml of tetracycline was
added to the stable cell lines to induce the expression of TDP-
FLAG or A90V-FLAG. After 48 h of induction, cells were washed
twice by 1XPBS and then replenished with fresh media without
tetracycline. Cells were collected at different time points (4–48 hrs)
after removing tetracycline. Harvested cells were lysed with RIPA
buffer or trizol (Ambion) to get whole cell protein extract or total
RNAs separately.
Statistical Analysis
Values are presented as mean 6 SEM. Statistical significance
was assessed by ANOVA or t test. P,0.05 was considered
significant.
Supporting Information
Figure S1 Karyotyping results show no chromosomal
abnormalities in control iPSC line 37L25 or patient iPSC
lines 36L11 and 36L3.
(TIF)
Figure S2 Neuronal subtypes in iPSC-derived neuronal
cultures. Most neurons are excitatory neurons and about 10%
are inhibitory neurons. The presence of the A90V mutation does
not affect the excitatory/inhibitory neuron ratio.
(TIF)
Figure S3 Cell viability does not differ in control and
patient neurons treated with 0.4 M sorbitol for 30
minutes (A), sodium arsenite (SA) (B) or t-butyl hydro-
peroxide (tBOOH) (C). Quantification of cell viability in
control and patient neurons after treatment with different stressors.
(TIF)
Figure S4 Cellular stress does not decrease FUS levels
in patient neurons but decreases TDP-43 mRNA. (A) FUS
level in the soluble fraction of control and patient neurons with
STS treatment. Quantification of the experiment is shown on the
right. (B) TDP-43 mRNA is decreased in patient neurons after
STS treatment as measured by qRT-PCR.
(TIF)
Figure S5 The protein stability and auto-regulation of
the wildtype and A90V mutant TDP-43. (A) Protein level of
transfected TDP-43 in TDP-43 or TDP-43 A90V-Flag stable cell
lines at different time point after tetracycline treatment. Endo
TDP-43: endogenous TDP-43. (B) Quantification of the experi-
ment in panel A. Values was normalized to transfected TDP-43 at
48 h after tetracycline treatment. (C) Induction of transfected
either TDP-43 WT or TDP-43 A90V at different time points leads
to gradual inhibition of endogenous TDP-43 (Endo TDP-43)
expression. There is no statistical difference in the extent of
autoregulation. (D) Quantification of the experiment in panel D.
In this experiment, the sample collected at 48 hr after tetracycline
induction appears to have higher protein level of TDP-43 WT
than TDP-43 A90V, which is due to higher transfection since the
wildtype mRNA is also higher (not shown).
(TIF)
Figure S6 Expression of miR-124 does not change in
patient and control neurons treated with STS or in
primary mouse neurons after TDP-43 knockdown. (A)
Expression of pri-miR-124-1 in neurons derived from two control
and three patient iPSC lines with or without STS treatment. (B)
Average expression of pri-miR-124-1 in control and patient
neurons. (C) Expression of pri-miR-124-1 in primary mouse
neurons transfected with TDP-43 shRNA.
(TIF)
Table S1 Primer sequences used in this study.
(DOC)
File S1 Patient information. The patient’s clinical symptoms
and family history are described in detail.
(DOCX)
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